托烷司琼、地塞米松联合奥美拉唑防治化疗所致恶心呕吐的效果观察
|
摘要
目的:探讨托烷司琼、地塞米松联合奥美拉唑防治化疗所致恶心呕吐的效果。方法:应用随机数字表法将笔者所在医院2018年3-12月收治的100例待化疗的患者分为观察组和对照组,每组50例。对照组患者给予托烷司琼治疗,观察组患者给予托烷司琼、地塞米松+奥美拉唑联合治疗。对照组和观察组均在化疗前后接受药物治疗,并在化疗第1天和化疗第3天计算患者的恶心呕吐评分;在治疗6 d时评价两种治疗方法的效果;及时监测患者的各种不良反应,计算不良反应发生率并对用药后的安全性进行评价。结果:治疗后两组的恶心呕吐评分均有所改善,且观察组的恶心呕吐改善评分均优于对照组,差异均有统计学意义(P<0.05);观察组治疗总有效率92.00%,显著高于对照组的68.00%,差异有统计学意义(P<0.05);观察组的不良反应发生率为18.00%,高于对照组的10.00%,差异有统计学意义(P<0.05)。结论:托烷司琼、地塞米松联合奥美拉唑能够有效防治化疗所致恶心呕吐,且用药安全。
Objective:To explore the efficacy of Tropisetron,Dexamethasone combined with Omeprazole in the prevention and treatment of chemotherapy-induced nausea and vomiting.Method:A total of 100 patients to be treated with chemotherapy from March to December 2018 were divided into observation group and control group according to the random number table method,with 50 cases in each group.The control group was treated with Tropisetron,and the observation group was given Tropisetron,Dexamethasone and Omeprazole.Both of the control group and observation group were given drug therapy before and after chemotherapy,and the score of nausea and vomiting was calculated on the 1 st day and the 3 rd day of chemotherapy.The efficacy of the two treatment methods was evaluated on the 6 th day of treatment.The various adverse reactions of patients were monitored in time,and the incidence rate of adverse reactions was calculated,and the safety after administration was evaluated.Result:After treatment,the nausea and vomiting points improved in the two groups,and the improvement of nausea and vomiting points in observation group were better than those in control group,the differences were statistically significant(P<0.05).The total effective rate of treatment in observation group was significantly higher than that in control group(92.00% vs 68.00%),the difference was statistically significant(P<0.05).The incidence rate of adverse reactions in observation group was higher than that in control group(18.00% vs 10.00%),the difference was statistically significant(P<0.05).Conclusion:Tropisetron,Dexamethasone combined with Omeprazole can effectively prevent and treat chemotherapy-induced nausea and vomiting,and it has medicine safety.
Objective:To explore the efficacy of Tropisetron,Dexamethasone combined with Omeprazole in the prevention and treatment of chemotherapy-induced nausea and vomiting.Method:A total of 100 patients to be treated with chemotherapy from March to December 2018 were divided into observation group and control group according to the random number table method,with 50 cases in each group.The control group was treated with Tropisetron,and the observation group was given Tropisetron,Dexamethasone and Omeprazole.Both of the control group and observation group were given drug therapy before and after chemotherapy,and the score of nausea and vomiting was calculated on the 1 st day and the 3 rd day of chemotherapy.The efficacy of the two treatment methods was evaluated on the 6 th day of treatment.The various adverse reactions of patients were monitored in time,and the incidence rate of adverse reactions was calculated,and the safety after administration was evaluated.Result:After treatment,the nausea and vomiting points improved in the two groups,and the improvement of nausea and vomiting points in observation group were better than those in control group,the differences were statistically significant(P<0.05).The total effective rate of treatment in observation group was significantly higher than that in control group(92.00% vs 68.00%),the difference was statistically significant(P<0.05).The incidence rate of adverse reactions in observation group was higher than that in control group(18.00% vs 10.00%),the difference was statistically significant(P<0.05).Conclusion:Tropisetron,Dexamethasone combined with Omeprazole can effectively prevent and treat chemotherapy-induced nausea and vomiting,and it has medicine safety.
引文
[1]张雪峰,彭云云,胡燕.预防奥沙利铂化疗后恶心呕吐方案的比较[J].贵州医药,2019,43(1):67-69.
[2]李娜,钟云萍,孙圣荣.渐进式肌肉放松训练缓解乳腺癌化疗期恶心呕吐的效果[J].上海护理,2019,19(1):10-13.
[3]丁士超.调中降逆方对非小细胞肺癌患者化疗相关恶心呕吐的作用及机制[J].山东医药,2019,59(1):58-60.
[4]黄妹妹,罗瑞君.放松训练对化疗患者预期性恶心呕吐的效果观察[J].护士进修杂志,2019,34(2):171-172.
[5]李洪海,韩琦,李萍,等.丁郁柿蒂汤调控5-HT、5-HT3R干预急性CINV的机制研究[J].中医药信息,2019,36(1):16-20.
[6]阿里木江·司马义,王晓丽,徐桂萍,等.托烷司琼联合地塞米松对腹腔镜食管裂孔疝修补术患者术后恶心呕吐的影响[J].中国医药,2019,14(2):268-270.
[7]朱玛,陈宝妫.两种托烷司琼给药方式预防腹腔镜子宫切除术后恶心呕吐的疗效观察[J].上海医药,2018,39(21):26-28.
[9]鲁学文,刘月江.托烷司琼复合地塞米松对扁桃体切除术患儿术后恶心呕吐的预防效果[J].安徽医学,2018,39(12):1479-1481.
[10]赵晔,王韶华,朱燕.内镜下止血夹联合奥美拉唑治疗消化性溃疡合并出血疗效观察[J].临床军医杂志,2018,46(7):812-813,815.
[11]吴祥,朱冬菊.奥美拉唑对婴儿上消化道出血血清炎症因子及免疫功能影响[J].中国急救复苏与灾害医学杂志,2019,14(2):145-147.
[12]赵扬,孙岩峰,苗丽霞,等.托烷司琼联合地塞米松、奥美拉唑防治儿童化疗相关性恶心呕吐108例[J].武警医学,2017,28(12):1265-1267.
[13]阿里木江·司马义,王晓丽,徐桂萍,等.托烷司琼联合地塞米松对腹腔镜食管裂孔疝修补术患者术后恶心呕吐的影响[J].中国医药,2019,14(2):268-270.
[14]刘中飞,陈永钧,李芹,等.NK-1受体抑制剂联合地塞米松与5-HT3受体抑制剂预防和治疗以卡铂为基础的化疗导致的恶心呕吐的疗效与安全性的Meta分析[J].中国药房,2018,29(23):3269-3274.
[15]高洁,毕翻利,党璐,等.帕洛诺司琼/昂丹司琼与地塞米松联用对腹腔镜子宫切除术后恶心呕吐比较[J].湖南师范大学学报:医学版,2018,15(6):45-46.
[2]李娜,钟云萍,孙圣荣.渐进式肌肉放松训练缓解乳腺癌化疗期恶心呕吐的效果[J].上海护理,2019,19(1):10-13.
[3]丁士超.调中降逆方对非小细胞肺癌患者化疗相关恶心呕吐的作用及机制[J].山东医药,2019,59(1):58-60.
[4]黄妹妹,罗瑞君.放松训练对化疗患者预期性恶心呕吐的效果观察[J].护士进修杂志,2019,34(2):171-172.
[5]李洪海,韩琦,李萍,等.丁郁柿蒂汤调控5-HT、5-HT3R干预急性CINV的机制研究[J].中医药信息,2019,36(1):16-20.
[6]阿里木江·司马义,王晓丽,徐桂萍,等.托烷司琼联合地塞米松对腹腔镜食管裂孔疝修补术患者术后恶心呕吐的影响[J].中国医药,2019,14(2):268-270.
[7]朱玛,陈宝妫.两种托烷司琼给药方式预防腹腔镜子宫切除术后恶心呕吐的疗效观察[J].上海医药,2018,39(21):26-28.
[9]鲁学文,刘月江.托烷司琼复合地塞米松对扁桃体切除术患儿术后恶心呕吐的预防效果[J].安徽医学,2018,39(12):1479-1481.
[10]赵晔,王韶华,朱燕.内镜下止血夹联合奥美拉唑治疗消化性溃疡合并出血疗效观察[J].临床军医杂志,2018,46(7):812-813,815.
[11]吴祥,朱冬菊.奥美拉唑对婴儿上消化道出血血清炎症因子及免疫功能影响[J].中国急救复苏与灾害医学杂志,2019,14(2):145-147.
[12]赵扬,孙岩峰,苗丽霞,等.托烷司琼联合地塞米松、奥美拉唑防治儿童化疗相关性恶心呕吐108例[J].武警医学,2017,28(12):1265-1267.
[13]阿里木江·司马义,王晓丽,徐桂萍,等.托烷司琼联合地塞米松对腹腔镜食管裂孔疝修补术患者术后恶心呕吐的影响[J].中国医药,2019,14(2):268-270.
[14]刘中飞,陈永钧,李芹,等.NK-1受体抑制剂联合地塞米松与5-HT3受体抑制剂预防和治疗以卡铂为基础的化疗导致的恶心呕吐的疗效与安全性的Meta分析[J].中国药房,2018,29(23):3269-3274.
[15]高洁,毕翻利,党璐,等.帕洛诺司琼/昂丹司琼与地塞米松联用对腹腔镜子宫切除术后恶心呕吐比较[J].湖南师范大学学报:医学版,2018,15(6):45-46.